Home › Rhabdomyosarcoma
Rhabdomyosarcoma clinical trials recruiting in the U.S.
26 studies for Rhabdomyosarcoma are recruiting participants at sites across the United States.
Cities with the most studies
- Houston, TX6 studies
- Memphis, TN6 studies
- Washington, DC5 studies
- Salt Lake City, UT4 studies
- Boston, MA4 studies
- Philadelphia, PA4 studies
- Dallas, TX3 studies
- Birmingham, AL3 studies
- Aurora, CO3 studies
- Baltimore, MD3 studies
- The Bronx, NY3 studies
- Seattle, WA3 studies
By state
- Alabama3 studies
- California7 studies
- Colorado3 studies
- District of Columbia4 studies
- Florida3 studies
- Maryland4 studies
- Massachusetts4 studies
- New York4 studies
- Ohio5 studies
- Pennsylvania5 studies
- Tennessee8 studies
- Texas9 studies
- Utah4 studies
- Washington3 studies
Recently updated studies
FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma
RecruitingPhase 1
Ages 3 to 39 · All sexes · Updated Sep 29, 2026 · NCT06865664Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
RecruitingPhase 1
24 Months – 18 Years · All sexes · Updated Sep 25, 2026 · NCT06441331Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
RecruitingPhase 1/2
Up to age 30 · All sexes · Updated Sep 3, 2026 · NCT06541262A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)
RecruitingPhase 3
Up to age 50 · All sexes · Updated Aug 25, 2026 · NCT07466316Integration of Adaptive Proton Therapy in Pediatric Solid Tumors and Hodgkin's Lymphoma
Recruiting
All ages · All sexes · Updated Aug 21, 2026 · NCT07514819Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)
RecruitingPhase 1
Ages 1 to 23 · All sexes · Updated Aug 13, 2026 · NCT07172958Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
RecruitingPhase 1
Ages 1 to 21 · All sexes · Updated Aug 6, 2026 · NCT04715191Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 6, 2026 · NCT05210374Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors
RecruitingEarly phase 1
Ages 18 and older · All sexes · Updated Jul 31, 2026 · NCT07628634PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
RecruitingPhase 1/2
Ages 1 to 30 · All sexes · Updated Jul 22, 2026 · NCT06721689Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma
Recruiting
Up to age 39 · All sexes · Updated Jul 13, 2026 · NCT06796543Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
RecruitingPhase 1/2
6 Months – 25 Years · All sexes · Updated Jun 30, 2026 · NCT06625190Familial Investigations of Childhood Cancer Predisposition
RecruitingObservational study
All ages · All sexes · Updated Jun 17, 2026 · NCT03050268Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease
RecruitingPhase 2
Up to age 22 · All sexes · Updated Jun 15, 2026 · NCT06023641VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors
RecruitingPhase 1/2
6 Months – 30 Years · All sexes · Updated Jun 2, 2026 · NCT04796012Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
RecruitingPhase 1/2
12 Months – 30 Years · All sexes · Updated May 19, 2026 · NCT04901702B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
RecruitingPhase 1
Up to age 21 · All sexes · Updated May 19, 2026 · NCT04897321Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies
RecruitingPhase 1
Ages 1 to 30 · All sexes · Updated Apr 15, 2026 · NCT04308330Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
RecruitingPhase 2
Ages 1 to 50 · All sexes · Updated Mar 13, 2026 · NCT01804634Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas
RecruitingPhase 1/2
Ages 12 to 49 · All sexes · Updated Feb 19, 2026 · NCT06709495Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells
RecruitingPhase 1
Ages 1 to 26 · All sexes · Updated Feb 17, 2026 · NCT07148050HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
RecruitingPhase 1
Ages 1 to 25 · All sexes · Updated Jan 22, 2026 · NCT04995003Molecular Analysis Of Solid Tumors
RecruitingObservational study
Up to age 25 · All sexes · Updated Nov 12, 2025 · NCT01050296Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
RecruitingPhase 1
Up to age 21 · All sexes · Updated Nov 3, 2025 · NCT06198296Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
RecruitingPhase 1
7 Months – 21 Years · All sexes · Updated Oct 16, 2025 · NCT02508038From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.